A 96-week comparison of lopinavir-ritonavir combination therapy followed by lopinavir-ritonavir monotherapy versus efavirenz combination therapy

被引：92

作者：

Cameron, D. William ^{[1
]}

da Silva, Barbara A. ^{[3
]}

Arribas, Jose R. ^{[6
]}

Myers, Robert A. ^{[4
]}

Bellos, Nicholaos C. ^{[5
]}

Gilmore, Norbert ^{[2
]}

King, Martin S. ^{[3
]}

Bernstein, Barry M. ^{[3
]}

Brun, Scott C. ^{[3
]}

Hanna, George J. ^{[3
]}

机构：

[1] Univ Ottawa, Ottawa Hosp, Div Infect Dis, Ottawa, ON, Canada

[2] McGill Univ, Ctr Hlth, Montreal, PQ, Canada

[3] Abbott Labs, Abbott Pk, IL 60064 USA

[4] Body Posit Inc, Phoenix, AZ USA

[5] SW Infect Dis Associates, Dallas, TX USA

[6] Hosp La Paz, Madrid, Spain

来源：

JOURNAL OF INFECTIOUS DISEASES | 2008年 / 198卷 / 02期

关键词：

D O I：

10.1086/589622

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Antiretroviral-naive HIV-1-infected volunteers received zidovudine/lamivudine plus either lopinavir/ritonavir (n = 104) or efavirenz (n = 51). Lopinavir/ritonavir-treated subjects demonstrating 3 consecutive monthly HIV-1 RNA levels <50 copies/mL started lopinavir/ritonavir monotherapy. In previous-failure = failure analysis, 48% (lopinavir/ritonavir) and 61% (efavirenz) maintained HIV-1 RNA at <50 copies/mL through week 96, (P = .17; 95% confidence interval [CI] for the difference, -29% to 4%); in noncompletion = failure analysis, 60% (lopinavir/ritonavir) and 63% (efavirenz) maintained HIV-1 RNA at < 50 copies/ mL at week 96 (P = .73; 95% CI for the difference, -19% to 13%). Significant sparing of peripheral lipoatrophy was noted in the lopinavir/ritonavir simplification strategy. This study has provided important information for future studies using treatment simplified to lopinavir/ritonavir monotherapy.

引用

页码：234 / 240

页数：7

共 50 条

[41] Monotherapy with darunavir/ritonavir or lopinavir/ritonavir versus standard antiretroviral therapy: a randomized clinical trial (2pm Study)
Gianotti, Nicola
Galli, Laura
Maserati, Renato
Sighinolfi, Laura
Ripamonti, Diego
Palvarini, Loredana
Lo Caputo, Sergio
Foca, Emanuele
Celesia, Benedetto Maurizio
Baldelli, Franco
Sterrantino, Gaetana
Lazzarin, Adriano
NEW MICROBIOLOGICA, 2016, 39 (04): : 290 - 294
[42] Neurocognitive impairment in patients randomized to second-line lopinavir/ritonavir-based antiretroviral therapy vs. lopinavir/ritonavir monotherapy
Bunupuradah, Torsak
Chetchotisakd, Ploenchan
Jirajariyavej, Supunnee
Valcour, Victor
Bowonwattanuwong, Chureeratana
Munsakul, Warangkana
Klinbuayaem, Virat
Prasithsirikul, Wisit
Sophonphan, Jiratchaya
Mahanontharit, Apicha
Hirschel, Bernard
Bhakeecheep, Sorakij
Ruxrungtham, Kiat
Ananworanich, Jintanat
JOURNAL OF NEUROVIROLOGY, 2012, 18 (06) : 479 - 487
[43] Neurocognitive impairment in patients randomized to second-line lopinavir/ritonavir-based antiretroviral therapy vs. lopinavir/ritonavir monotherapy
Torsak Bunupuradah
Ploenchan Chetchotisakd
Supunnee Jirajariyavej
Victor Valcour
Chureeratana Bowonwattanuwong
Warangkana Munsakul
Virat Klinbuayaem
Wisit Prasithsirikul
Jiratchaya Sophonphan
Apicha Mahanontharit
Bernard Hirschel
Sorakij Bhakeecheep
Kiat Ruxrungtham
Jintanat Ananworanich
Journal of NeuroVirology, 2012, 18 : 479 - 487
[44] The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial
Eron, Joseph, Jr.
Yeni, Patrick
Gathe, Joseph, Jr.
Estrada, Vicente
DeJesus, Edwin
Staszewski, Schlamo
Lackey, Philip
Katlama, Christine
Young, Benjamin
You, Linda
Sutherland-Phillips, Denise
Wannamaker, Paul
Vavro, Cindy
Patel, Lisa
Yeo, Jane
Shaefer, Mark
LANCET, 2006, 368 (9534): : 476 - 482
[45] Favipiravir, lopinavir-ritonavir, or combination therapy (FLARE): A randomised, double-blind, 2 x 2 factorial placebo-controlled trial of early antiviral therapy in COVID-19
Lowe, David M.
Brown, Li-An K.
Chowdhury, Kashfia
Davey, Stephanie
Yee, Philip
Ikeji, Felicia
Ndoutoumou, Amalia
Shah, Divya
Lennon, Alexander
Rai, Abhulya
Agyeman, Akosua A.
Checkley, Anna
Longley, Nicola
Dehbi, Hakim-Moulay
Freemantle, Nick
Breuer, Judith
Standing, Joseph F.
PLOS MEDICINE, 2022, 19 (10)
[46] Darunavir-cobicistat versus lopinavir-ritonavir in the treatment of COVID-19 infection (DOLCI): A multicenter observational study
Elmekaty, Eman Zeyad, I
Alibrahim, Rim
Hassanin, Rania
Eltaib, Sitelbanat
Elsayed, Ahmed
Rustom, Fatima
Ibrahim, Mohamed Izham Mohamed
Abu Khattab, Mohammed
Al Soub, Hussam
Al Maslamani, Muna
Al-Khal, Abdullatif
PLOS ONE, 2022, 17 (05):
[47] Differential Subcutaneous Adipose Tissue Gene Expression Patterns in a Randomized Clinical Trial of Efavirenz or Lopinavir-Ritonavir in Antiretroviral-Naive Patients
Egana-Gorrono, L.
Martinez, E.
Domingo, P.
Lonca, M.
Escriba, T.
Fontdevila, J.
Vidal, F.
Negredo, E.
Gatell, J. M.
Arnedo, M.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2014, 58 (11) : 6717 - 6723
[48] Virologic Failure in Therapy-Naive Subjects on Aplaviroc plus Lopinavir-Ritonavir: Detection of Aplaviroc Resistance Requires Clonal Analysis of Envelope
Kitrinos, Kathryn M.
Amrine-Madsen, Heather
Irlbeck, David M.
Word, J. Michael
Demarest, James F.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2009, 53 (03) : 1124 - 1131
[49] A randomized comparison of second-line lopinavir/ritonavir monotherapy versus tenofovir/lamivudine/lopinavir/ritonavir in patients failing NNRTI regimens: the HIV STAR study
Bunupuradah, Torsak
Chetchotisakd, Ploenchan
Ananworanich, Jintanat
Munsakul, Warangkana
Jirajariyavej, Supunnee
Kantipong, Pacharee
Prasithsirikul, Wisit
Sungkanuparph, Somnuek
Bowonwatanuwong, Chureeratana
Klinbuayaem, Virat
Kerr, Stephen J.
Sophonphan, Jiratchaya
Bhakeecheep, Sorakij
Hirschel, Bernard
Ruxrungtham, Kiat
ANTIVIRAL THERAPY, 2012, 17 (07) : 1351 - 1361
[50] A comparison of dyslipidemias associated with either lopinavir/ritonavir- or indinavir/ritonavir-based antiretroviral therapy
Antoniou, T
Park-Wyllie, L
Boyle, E
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2004, 37 (05) : 1666 - 1667

← 1 2 3 4 5 →